NCT06402110

Brief Summary

The aim of this study is to compare the postoperative analgesic effect of femoral triangle block (FTB) and adductor canal block (ACB)after arthroscopic anterior cruciate ligament (ACL) reconstruction.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 2, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 7, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

May 7, 2024

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 27, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 27, 2025

Completed
Last Updated

July 31, 2025

Status Verified

July 1, 2025

Enrollment Period

12 months

First QC Date

May 2, 2024

Last Update Submit

July 30, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total morphine consumption

    Rescue analgesia of 3 mg morphine IV will be given if the Numeric Rating Scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4. NRS will be assessed at 2, 4, 6, 12, and 24h postoperatively

    24 hours postoperatively

Secondary Outcomes (4)

  • Time of 1st rescue analgesia

    24 hours postoperatively

  • Pain score using Numeric Rating Scale (NRS)

    24 hours postoperatively

  • Quadriceps strength

    24 hours postoperatively

  • Patient satisfaction

    24 hours postoperatively

Study Arms (2)

Femoral Triangle Block (FTB) Group

EXPERIMENTAL

Patients will receive femoral triangle block (FTB) at the end of surgery.

Other: Femoral Triangle Block

Adductor Canal Block (ACB) Group

EXPERIMENTAL

Patients will receive adductor canal block (ACB) at the end of surgery.

Other: Adductor Canal Block

Interventions

Patients will receive femoral triangle block (FTB) at the end of surgery. The probe will be positioned at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle, a block needle advanced in an in-plane technique into femoral triangle. After negative aspiration, 2ml of saline will be injected to confirm the needle tip position close to the femoral artery then injection of 15ml of bupivacaine 0.25% will be performed.

Femoral Triangle Block (FTB) Group

Patients will receive adductor canal block (ACB) at the end of surgery. The probe will be positioned at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the Sartorius muscle and a block needle advanced in an in-plane technique toward the target nerve after negative aspiration, 2ml of saline will be injected into adductor canal to confirm the block needle tip within it, the block needle will be advanced with the guidance of ultrasound in an in-plane technique and 15ml bupivacaine 0.25% will be injected.

Adductor Canal Block (ACB) Group

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age from 21 to 65 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I and II.
  • Undergoing elective arthroscopic Anterior Cruciate Ligament (ACL) reconstruction.

You may not qualify if:

  • Revisional surgery.
  • Body mass index (BMI) \>35kg/m2.
  • Coagulopathy.
  • Infection at site of intervention.
  • Hypersensitive to the study drugs.
  • Chronic analgesic use.
  • Neuromuscular disease.
  • Drug abuse.
  • Cognitive impairment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

First Submitted

May 2, 2024

First Posted

May 7, 2024

Study Start

May 7, 2024

Primary Completion

April 27, 2025

Study Completion

April 27, 2025

Last Updated

July 31, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Shared Documents
STUDY PROTOCOL
Time Frame
After the end of study for one year.
Access Criteria
The data will be available upon a reasonable request from the corresponding author.

Locations